1. Home
  2. ERAS vs MPB Comparison

ERAS vs MPB Comparison

Compare ERAS & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • MPB
  • Stock Information
  • Founded
  • ERAS 2018
  • MPB 1868
  • Country
  • ERAS United States
  • MPB United States
  • Employees
  • ERAS N/A
  • MPB N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • MPB Major Banks
  • Sector
  • ERAS Health Care
  • MPB Finance
  • Exchange
  • ERAS Nasdaq
  • MPB Nasdaq
  • Market Cap
  • ERAS 396.6M
  • MPB 467.7M
  • IPO Year
  • ERAS 2021
  • MPB N/A
  • Fundamental
  • Price
  • ERAS $1.39
  • MPB $28.20
  • Analyst Decision
  • ERAS Strong Buy
  • MPB Buy
  • Analyst Count
  • ERAS 6
  • MPB 2
  • Target Price
  • ERAS $4.83
  • MPB $36.00
  • AVG Volume (30 Days)
  • ERAS 1.4M
  • MPB 132.4K
  • Earning Date
  • ERAS 05-20-2025
  • MPB 04-23-2025
  • Dividend Yield
  • ERAS N/A
  • MPB 2.82%
  • EPS Growth
  • ERAS N/A
  • MPB 23.94
  • EPS
  • ERAS N/A
  • MPB 2.88
  • Revenue
  • ERAS N/A
  • MPB $181,865,000.00
  • Revenue This Year
  • ERAS N/A
  • MPB $19.07
  • Revenue Next Year
  • ERAS N/A
  • MPB $11.53
  • P/E Ratio
  • ERAS N/A
  • MPB $10.05
  • Revenue Growth
  • ERAS N/A
  • MPB 8.94
  • 52 Week Low
  • ERAS $1.01
  • MPB $19.75
  • 52 Week High
  • ERAS $3.45
  • MPB $33.87
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 51.46
  • MPB 56.40
  • Support Level
  • ERAS $1.37
  • MPB $26.16
  • Resistance Level
  • ERAS $1.61
  • MPB $29.57
  • Average True Range (ATR)
  • ERAS 0.14
  • MPB 1.16
  • MACD
  • ERAS 0.00
  • MPB 0.09
  • Stochastic Oscillator
  • ERAS 45.68
  • MPB 63.93

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.

Share on Social Networks: